Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy (Q33769702)

29 July 2017

1 reference

title

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy (English)

1 reference

29 July 2017

1 reference

1

Champlin R

1 reference

29 July 2017

8

Giralt S

1 reference

29 July 2017

2

Khouri I

1 reference

29 July 2017

Kornblau S

3

1 reference

29 July 2017

Marini F

4

1 reference

29 July 2017

Anderlini P

5

1 reference

29 July 2017

Ueno NT

6

1 reference

29 July 2017

Molldrem J

7

1 reference

29 July 2017

1 October 1999

1 reference

Hematology / Oncology Clinics of North America

29 July 2017

1 reference

29 July 2017

13

1 reference

29 July 2017

5

1 reference

29 July 2017

1041-57, vii-viii

1 reference

Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Antigen presentation: a balanced diet

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

How does bone-marrow transplantation cure leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Identical-twin bone marrow transplants for leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Minor histocompatibility antigens and marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

T cell subsets and graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Donor leucocyte transfusions for relapse in myelodyplastic syndrome after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Lymphocytes with a CD4+ CD8- CD3- phenotype are effectors of experimental cutaneous graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Graft-versus-myeloma effect in two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970108-8

7 January 2021

10.1016/S0889-8588(05)70108-8

Identifiers

DOI

1 reference

29 July 2017

1 reference